The ABPI responded to Radio 4's File on Four programme on opioids, which examined whether there are any similarities between the way in which opioid medications are being marketed by pharmaceutical companies in the US and the UK.
The Migration Advisory Committee has published their full review of the shortage occupation list (SOL) and recommended that a number of fields be added to the list.
Life sciences is among a select group of highly innovative industries linked to science and tech which could be responsible for a new wave of growth worth an extra £14 billion a year to the UK economy by 2025.
Health Secretary Matt Hancock has announced that all opioid medicines in the UK will carry prominent warnings on the labels saying they can cause addiction.
The Department of Health and Social Care today published the 2019 update of their Implementation Plan for England for the UK Strategy for Rare Diseases. This sets out progress made against the original commitments in the Strategy.
A Europe-wide initiative to protect patients and public health from falsified or fake medicines goes live on Saturday 9 February 2019, making the medicines supply chain across Europe safer than ever before.
The Chancellor has announced a £100 million investment for research and technology.
As the UK prepares to leave the EU, the House of Lords is debating a Statutory Instrument which would weaken the UK’s IP framework and damage the country’s reputation as leader in life sciences.
Lisa Anson, President of the ABPI, closing remarks to the ABPI Annual Conference on the future of UK life sciences.
Mike Thompson, chief executive of the ABPI, opening address to the ABPI Annual Conference outlining the strength of the industry and looking ahead to the next 70 years.
A report published by the Business, Energy and Indsutrial Strategy (BEIS) Strategy Committee, calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry.